Mineralys Therapeutics announced on March 17, 2025, that data from its Phase 2 Advance-HTN trial has been accepted for a late-breaking clinical trials session. The presentation will occur at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25), held in Chicago from March 29-31, 2025.
This acceptance highlights the significance of the efficacy and safety data for lorundrostat in treating uncontrolled or resistant hypertension. A late-breaking presentation slot is typically reserved for highly impactful and timely clinical research.
The presentation at a prominent cardiology conference will provide detailed insights into lorundrostat's performance to a broad audience of medical professionals and researchers. This exposure further validates the trial results and the drug's potential in the hypertension landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.